Physician profile
John G Elder
NPI 1366454225
$52,466.97
in general payments reported to CMS, 2019-2025
27 companies · $66.96 in 2025
The $66.96 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $4,991 · 2021: $554 · 2022: $293 · 2023: $20.57 · 2025: $66.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $87.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $87.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $48,712.01 | 2019-2020 | |
| Amgen INC. | $840.56 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $435.64 | 2019-2020 | |
| Genentech USA, INC. | $330.80 | 2019-2020 | |
| Horizon Therapeutics Plc | $281.58 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $273.86 | 2019-2023 | Farxiga |
| Fresenius USA Marketing, INC. | $257.47 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $225.69 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $221.98 | 2019-2020 | |
| Genzyme Corporation | $153.05 | 2019-2020 | |
| Glaxosmithkline, LLC. | $127.82 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $119.40 | 2019 | |
| Amag Pharmaceuticals, INC. | $85.07 | 2019-2021 | |
| Amicus Therapeutics, INC. | $58.61 | 2019-2021 | |
| Janssen Biotech, INC. | $44.36 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lemaitre Vascular, INC. | $40.22 | 2025 | Artegraft Vascular Graft |
| Lilly USA, LLC | $38.28 | 2021 | |
| Mallinckrodt Hospital Products INC. | $34.07 | 2020 | |
| Mallinckrodt Enterprises LLC | $27.15 | 2019 | |
| Sandoz INC. | $26.74 | 2025 | Jubbonti |
| Pfizer INC. | $25.82 | 2019 | |
| Bioventus LLC | $24.91 | 2020 | |
| Radius Health, INC. | $24.20 | 2021 | |
| Celgene Corporation | $20.58 | 2019 | |
| Shire North American Group INC | $18.68 | 2019 | |
| Nxstage Medical, INC. | $18.42 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Elder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.